Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carrier solutions for intraperitoneal chemotherapy.

Faheez Mohamed1, Paul H Sugarbaker

  • 1Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA.

Surgical Oncology Clinics of North America
|October 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphology and Pathophysiology of 10 Different Types of Peritoneal Metastases.

Journal of surgical oncology·2026
Same author

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be safely combined with nephrectomy in patients with appendiceal malignancy and synchronous renal cell carcinoma.

Journal of surgical case reports·2026
Same author

Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years.

Journal of surgical oncology·2026
Same author

Response to Letter Comments on Raised Serum Tumor Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC.

Annals of surgical oncology·2026
Same author

ASO Visual Abstract: MORPHology and Inter-Observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS-The MORPHEUS Study.

Annals of surgical oncology·2026
Same author

Correction: MORPHology and Inter-observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS: The MORPHEUS study.

Annals of surgical oncology·2026

Choosing the right carrier solution is key for effective intraperitoneal chemotherapy. High molecular weight solutions may improve drug delivery and tumor penetration compared to standard glucose or saline carriers.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Delivery Systems

Background:

  • Intraperitoneal chemotherapy faces challenges with poor tumor penetration and uneven drug distribution.
  • Understanding carrier solution pharmacodynamics is crucial for improving treatment efficacy.

Purpose of the Study:

  • To explore the impact of carrier solution properties on intraperitoneal chemotherapy effectiveness.
  • To identify optimal carrier solutions for enhancing drug delivery and tumor penetration.

Main Methods:

  • Analysis of pharmacokinetic and pharmacodynamic properties of various carrier solutions.
  • Comparison of high molecular weight solutions with low molecular weight glucose and saline solutions.

Main Results:

Related Experiment Videos

  • High molecular weight solutions show potential advantages for high molecular weight chemotherapeutic agents.
  • These solutions may overcome limitations of poor tumor penetration and nonuniform distribution.

    • Conclusions:

    • Matching drugs with appropriate high molecular weight carrier solutions can enhance intraperitoneal chemotherapy.
    • Further research into carrier solutions with varying tonicity is warranted.